Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer By Ogkologos - August 17, 2026 79 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PSMAddition study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR A New Study Suggests Screen Time Might Not Be The Worst... November 14, 2019 FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma October 27, 2025 Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... December 15, 2020 Malaria Vaccine Approved by W.H.O. Could Save Tens Of Thousands Of... October 7, 2021 Load more HOT NEWS Pregnancy is Safe After Early Breast Cancer in Young Women with... Cancer Research UK reports record levels of investment in its spinouts FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib...
